NASDAQ:HSIC - Henry Schein Stock Price, Price Target & More

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Henry Schein's stock split before market open on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly issued shares were issued to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein declared that its board has approved a share buyback plan on Tuesday, September 19th 2017, which allows the company to repurchase $400,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 6.3% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board believes its stock is undervalued.

Henry Schein, Inc. (NASDAQ:HSIC) posted its quarterly earnings results on Tuesday, May, 8th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.92 by $0.03. The business had revenue of $3.22 billion for the quarter, compared to analysts' expectations of $3.18 billion. Henry Schein had a return on equity of 19.68% and a net margin of 3.18%. The company's quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.88 EPS. View Henry Schein's Earnings History.

Henry Schein is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Henry Schein.

Henry Schein issued an update on its FY18 earnings guidance on Tuesday, May, 8th. The company provided EPS guidance of $4.03-4.14 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.09.

19 brokerages have issued 12 month price objectives for Henry Schein's shares. Their predictions range from $73.00 to $102.00. On average, they anticipate Henry Schein's stock price to reach $81.50 in the next twelve months. This suggests a possible upside of 10.5% from the stock's current price. View Analyst Ratings for Henry Schein.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 1 sell rating, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Henry Schein include FRESENIUS SE &/S (FSNUY), Illumina (ILMN), Express Scripts (ESRX), Humana (HUM), Zoetis (ZTS), BEXIMCO PHARMAC/S GDR REGS (BXP), Baxter International (BAX), Regeneron Pharmaceuticals (REGN), HCA Healthcare (HCA), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), ESSILOR Intl S/S (ESLOY), Edwards Lifesciences (EW), Fresenius Medical Care AG & Co. (FMS) and Alexion Pharmaceuticals (ALXN).

News articles about HSIC stock have trended somewhat positive recently, according to Accern. Accern ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Henry Schein earned a media sentiment score of 0.19 on Accern's scale. They also assigned headlines about the company an impact score of 46.51 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Henry Schein's stock is owned by a number of of institutional and retail investors. Top institutional investors include Swedbank (1.33%), Fenimore Asset Management Inc. (0.36%), Riverbridge Partners LLC (0.27%), Bank of Montreal Can (0.24%), Port Capital LLC (0.14%) and Fisher Asset Management LLC (0.07%). Company insiders that own Henry Schein stock include Barry J Alperin, Donald J Kabat, Gerald A Benjamin, James A Harding, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Swedbank, Bank of Montreal Can, Neville Rodie & Shaw Inc., Riverbridge Partners LLC, Gateway Investment Advisers LLC, Carderock Capital Management Inc. and Laurel Grove Capital LLC. Company insiders that have sold Henry Schein company stock in the last year include Barry J Alperin, Mark E Mlotek, Paul Brons and Paul Rose. View Insider Buying and Selling for Henry Schein.

HSIC stock was purchased by a variety of institutional investors in the last quarter, including Addenda Capital Inc., Xact Kapitalforvaltning AB, AMG National Trust Bank, Port Capital LLC, Addenda Capital Inc., State of Alaska Department of Revenue, Trust Co. of Oklahoma and DnB Asset Management AS. View Insider Buying and Selling for Henry Schein.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HSIC stock can currently be purchased for approximately $73.74.

Henry Schein has a market capitalization of $11.50 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]